Efficacy and Safety of Nebivolol and Rosuvastatin Combination Treatment in Patients with Concomitant Hypertension and Hyperlipidemia

References

• JohnsonML, PietzK, BattlemanDS, BeythRJ. Prevalence of comorbid hypertension and dyslipidemia and associated cardiovascular disease. Am J Manag Care. 2004;10:926–932.15617368
   PubMed Web of Science ®Google Scholar
• JacksonR, LawesCM, BennettDA, MilneRJ, RodgersA. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual’s absolute cardiovascular risk. Lancet. 2005;365:434–441. doi:10.1016/S0140-6736(05)70240-315680460
   PubMed Web of Science ®Google Scholar
• EmbersonJ. Evaluating the impact of population and high-risk strategies for the primary prevention of cardiovascular disease. Eur Heart J. 2004;25(6):484–491. doi:10.1016/j.ehj.2003.11.01215039128
   PubMed Web of Science ®Google Scholar
• MachF, BaigentC, CatapanoAL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2019.
   PubMed Web of Science ®Google Scholar
• WheltonPK, CareyRM, AronowWS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the american college of cardiology/american heart association task force on clinical practice guidelines. Hypertension. 2018;71:e13–e115.29133356
   PubMed Web of Science ®Google Scholar
• Hypertension in adults: diagnosis and management. NICE guideline [NG136]. National institute for health and care excellence; Published 2019 Available from: https://www.nice.org.uk/guidance/ng136. Accessed 313, 2020.
   Google Scholar
• MarketouM, GuptaY, JainS, VardasP. Differential metabolic effects of beta-blockers: an updated systematic review of nebivolol. Curr Hypertens Rep. 2017;19:22. doi:10.1007/s11906-017-0716-328283926
   PubMed Web of Science ®Google Scholar
• WilliamsB, ManciaG, SpieringW, et al. ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021–3104.30165516
   PubMed Web of Science ®Google Scholar
• MunzelT, GoriT. Nebivolol: the somewhat-different beta-adrenergic receptor blocker. J Am Coll Cardiol. 2009;54:1491–1499. doi:10.1016/j.jacc.2009.05.06619815121
   PubMed Web of Science ®Google Scholar
• National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143–3421.
   Google Scholar
• WeissRJ, WeberMA, CarrAA, SullivanWA. A randomized, double-blind, placebo-controlled parallel-group study to assess the efficacy and safety of nebivolol, a novel beta-blocker, in patients with mild to moderate hypertension. J Clin Hypertens. 2007;9:667–676. doi:10.1111/j.1524-6175.2007.06679.x
   PubMedGoogle Scholar
• GilesTD, KhanBV, LatoJ, BrenerL, MaY, LukicT. Nebivolol monotherapy in younger adults (younger than 55 years) with hypertension: a randomized, placebo-controlled trial. J Clin Hypertens. 2013;15:687–693. doi:10.1111/jch.12169
   Web of Science ®Google Scholar
• McKenneyJM. Efficacy and safety of rosuvastatin in treatment of dyslipidemia. Am J Health Syst Pharm. 2005;62:1033–1047. doi:10.1093/ajhp/62.10.103315901588
   PubMed Web of Science ®Google Scholar
• SaitoY, GotoY, DaneA, StruttK, RazaA. Randomized dose-response study of rosuvastatin in Japanese patients with hypercholesterolemia. J Atheroscler Thromb. 2003;10:329–336. doi:10.5551/jat.10.32915037821
   PubMedGoogle Scholar
• NeatonJD, WentworthD. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple risk factor intervention trial research group. Arch Intern Med. 1992;152:56–64. doi:10.1001/archinte.1992.004001300820091728930
   PubMed Web of Science ®Google Scholar
• SpannellaF, GiuliettiF, Di PentimaC, SarzaniR. Prevalence and control of dyslipidemia in patients referred for high blood pressure: the disregarded “double-trouble” lipid profile in overweight/obese. Adv Ther. 2019;36:1426–1437. doi:10.1007/s12325-019-00941-630953331
   PubMed Web of Science ®Google Scholar
• SzyndlerA, Stolarz-SkrzypekK, KuznetsovaT, et al. Fatal and nonfatal outcomes, incidence of hypertension, and blood pressure changes in relation to urinary sodium excretion. JAMA, 2011; 305: 1777–1785]. Kardiol Pol. 2011;69:1314–1315.22219120
   PubMed Web of Science ®Google Scholar
• DahlofB, DevereuxRB, KjeldsenSE, et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995–1003. doi:10.1016/S0140-6736(02)08089-311937178
   PubMed Web of Science ®Google Scholar
• ZanchettiA, BondMG, HennigM, et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European lacidipine study on atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation. 2002;106:2422–2427. doi:10.1161/01.CIR.0000039288.86470.DD12417537
   PubMed Web of Science ®Google Scholar
• PepineCJ, HandbergEM, Cooper-DeHoffRM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003;290:2805–2816. doi:10.1001/jama.290.21.280514657064
   PubMed Web of Science ®Google Scholar
• DahlofB, SeverPS, PoulterNR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366:895–906.16154016
   PubMed Web of Science ®Google Scholar
• Van NuetenL, DupontAG, VertommenC, GoyvaertsH, RobertsonJI. A dose-response trial of nebivolol in essential hypertension. J Hum Hypertens. 1997;11:139–144. doi:10.1038/sj.jhh.10003929140802
   PubMed Web of Science ®Google Scholar
• Cooper-DehoffR, CohenJD, BakrisGL, et al. Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]). Am J Cardiol. 2006;98:890–894. doi:10.1016/j.amjcard.2006.04.03016996868
   PubMed Web of Science ®Google Scholar
• ElliottWJ, MeyerPM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet. 2007;369:201–207. doi:10.1016/S0140-6736(07)60108-117240286
   PubMed Web of Science ®Google Scholar
• SeverP, DahlofB, PoulterN, et al. Potential synergy between lipid-lowering and blood-pressure-lowering in the anglo-scandinavian cardiac outcomes trial. Eur Heart J. 2006;27:2982–2988. doi:10.1093/eurheartj/ehl40317145722
   PubMed Web of Science ®Google Scholar
• FogariR, ZoppiA, LazzariP, et al. Comparative effects of nebivolol and atenolol on blood pressure and insulin sensitivity in hypertensive subjects with type II diabetes. J Hum Hypertens. 1997;11:753–757. doi:10.1038/sj.jhh.10005339416986
   PubMed Web of Science ®Google Scholar
• RizosE, BairaktariE, KostoulaA, et al. The combination of nebivolol plus pravastatin is associated with a more beneficial metabolic profile compared to that of atenolol plus pravastatin in hypertensive patients with dyslipidemia: a pilot study. J Cardiovasc Pharmacol Ther. 2003;8:127–134. doi:10.1177/10742484030080020612808486
   PubMedGoogle Scholar
• LacourciereY, PoirierL, LefebvreJ, ProvencherP, ArnottW. Comparative effects of a new cardioselective beta-blocker nebivolol and nifedipine sustained-release on 24-hour ambulatory blood pressure and plasma lipoproteins. J Clin Pharmacol. 1992;32:660–666. doi:10.1002/j.1552-4604.1992.tb05778.x1353507
   PubMed Web of Science ®Google Scholar
• OzyildizAG, ErogluS, BalU, AtarI, OkyayK, MuderrisogluH. Effects of carvedilol compared to nebivolol on insulin resistance and lipid profile in patients with essential hypertension. J Cardiovasc Pharmacol Ther. 2017;22:65–70. doi:10.1177/107424841664498727093951
   PubMed Web of Science ®Google Scholar
• PesantY, Marc-AureleJ, BielmannP, et al. Metabolic and antihypertensive effects of nebivolol and atenolol in normometabolic patients with mild-to-moderate hypertension. Am J Ther. 1999;6:137–147. doi:10.1097/00045391-199905000-0000410423656
   PubMedGoogle Scholar
• LewingtonS, WhitlockG, ClarkeR, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet. 2007;370:1829–1839.18061058
   PubMed Web of Science ®Google Scholar
• NordestgaardBG, VarboA. Triglycerides and cardiovascular disease. Lancet. 2014;384:626–635. doi:10.1016/S0140-6736(14)61177-625131982
   PubMed Web of Science ®Google Scholar
• BorenJ, WilliamsKJ. The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: a triumph of simplicity. Curr Opin Lipidol. 2016;27:473–483. doi:10.1097/MOL.000000000000033027472409
   PubMed Web of Science ®Google Scholar
• LaufsU, ParhoferKG, GinsbergHN, HegeleRA. Clinical review on triglycerides. Eur Heart J. 2020;41:99–109c. doi:10.1093/eurheartj/ehz78531764986
   PubMed Web of Science ®Google Scholar
• SattarN, PreissD, MurrayHM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375:735–742. doi:10.1016/S0140-6736(09)61965-620167359
   PubMed Web of Science ®Google Scholar
• KimS, ShinDW, YunJM, et al. Medication adherence and the risk of cardiovascular mortality and hospitalization among patients with newly prescribed antihypertensive medications. Hypertension. 2016;67:506–512. doi:10.1161/HYPERTENSIONAHA.115.0673126865198
   PubMed Web of Science ®Google Scholar
• BangaloreS, KamalakkannanG, ParkarS, MesserliFH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120:713–719. doi:10.1016/j.amjmed.2006.08.03317679131
   PubMed Web of Science ®Google Scholar
• WilliamsB, PoulterNR, BrownMJ, et al. Guidelines for management of hypertension: report of the fourth working party of the british hypertension society, 2004-BHS IV. J Hum Hypertens. 2004;18:139–185.14973512
   PubMed Web of Science ®Google Scholar
• SimovaII, Todorova-KonstantinovaRR, DenchevSV. Effects of nebivolol versus bisoprolol on endothelial function in hypertensive patients. Exp Clin Cardiol. 2009;14:45–49.20198199
   PubMedGoogle Scholar